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Inﬂammation is a major component in the pathology of chronic lung diseases, including asthma. Anti-inﬂammatory treatment
with corticosteroids is not eﬀective in all patients. Thus, new therapeutic options are required to control diverse cellular func-
tions that are currently not optimally targeted by these drugs in order to inhibit inﬂammation and its sequelae in lung disease.
Peroxisome proliferator activated receptors (PPARs), originally characterised as regulators of lipid and glucose metabolism, oﬀer
marked potential in this respect. PPARs are expressed in both lung inﬁltrating and resident immune and inﬂammatory cells, as
well as in resident and structural cells in the lungs, and play critical roles in the regulation of airway inﬂammation. In vitro, en-
dogenous and synthetic ligands for PPARs regulate expression and release of proinﬂammatory cytokines and chemoattractants,
and cell proliferation and survival. In murine models of allergen-induced inﬂammation, PPARα and PPARγ ligands reduce the
inﬂux of inﬂammatory cells, cytokine and mucus production, collagen deposition, and airways hyperresponsiveness. The activity
proﬁles of PPAR ligands diﬀer to corticosteroids, supporting the hypothesis that PPARs comprise additional therapeutic targets to
mimimise the contribution of inﬂammation to airway remodelling and dysfunction.
Copyright © 2007 J. E. Ward and X. Tan. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Current treatment for chronic lung diseases, including
asthma, targets the inﬂammatory response that is a major
contributor to disease pathology. Although inhaled corti-
costeroids are safe and eﬀective in most patients, a signiﬁ-
cant proportion of patients with asthma fail to obtain the
expected beneﬁts of anti-inﬂammatory treatment or suﬀer
a d v e r s es i d ee ﬀects, and these drugs have not been shown
to prevent disease progression. The involvement of diverse
cell types and mediators in the inﬂammatory process pro-
vides numerous potential therapeutic options in addition to
those targeted by corticosteroids. Novel anti-inﬂammatory
agents with diﬀerent activity proﬁles to corticosteroids may
minimise persistent inﬂammation and reduce its contribu-
tion to airway remodelling and airways hyperresponsiveness
(AHR) in asthma and the loss of pulmonary function in
other chronic inﬂammatory lung diseases.
Peroxisome proliferator activated receptors (PPARs) are
ligand-activated transcription factors that have recently been
implicated as targets for the regulation of inﬂammation.
PPARs are members of the nuclear hormone receptor fam-
ily with three isoforms, designated PPARα (NR1C1), PPARβ
(PPARδ, NR1C2), and PPARγ (NR1C3). Activation of these
receptors has been shown to regulate diverse cellular re-
sponses including production of immunomodulatory cy-
tokines, chemotaxis, cell diﬀerentiation, proliferation, and
survival. This review describes the localisation of these re-
ceptors in key cells involved in the pathogenesis of inﬂam-
matory diseases in the lung, and presents in vitro and in vivo
evidence describing the anti-inﬂammatory eﬃcacy of PPAR
ligands. The identiﬁcation of complementary or additional
actions to those exerted by corticosteroids supports further
exploration of the therapeutic potential of PPAR ligands in
asthma and chronic lung inﬂammation.
2. PPARs AND RXRs
The name PPAR derives from the identiﬁcation of PPARα as
the molecular target for the ﬁbrate class of drugs that induce2 PPAR Research
peroxisomeproliferationinrodents,apropertynotsharedby
the other PPAR isoforms. PPARα,P P A R β,a n dP P A R γ share
a common structure of 4 domains consisting of a variable
amino terminal activation function-1 domain (AF-1, A/B), a
DNA binding domain (C), a hinge region (D), and a highly
conserved activation function-2 domain (AF-2, E/F). The
large T-shaped ligand-binding domain within the AF-2 re-
gion enables PPARs to bind promiscuously to a plethora of
structurally diverse endogenous and synthetic ligands [1]. In
addition to ligand binding, AF-2 is important for association
withcoregulatorsofreceptoractivity,andforreceptordimer-
ization and nuclear translocation. Unlike glucocorticoid re-
ceptors that form homodimers, PPARs exist as heterodimers
with retinoid X receptors (RXR). Like PPARs, there are three
distinct isoforms of RXR, namely RXRα,R X R β,a n dR X R γ,
that are all activated by the endogenous ligand 9-cis retinoic
acid [2].
3. PROPOSED MECHANISMS OF GENE REGULATION
BY PPAR
The molecular mechanisms of gene regulation by PPARs are
complex. Heterodimerization of PPAR with RXR may be
aﬀected by competition between PPAR isoforms and with
other nuclear receptors that are also RXR partners, such as
retinoic acid receptors, vitamin D receptors, and liver X re-
ceptors. In the absence of ligand, PPAR-RXR forms a com-
plex with corepressor proteins with histone deacetylase ac-
tivity, including nuclear receptor corepressor (NCoR) and
the silencing mediator for retinoid and thyroid hormone re-
ceptors (SMRT) that prevents interaction with intracellular
targets. Ligand binding causes corepressor dissociation, and
ligand-dependent recruitment of coactivators such as steroid
receptor coactivator-1 (SRC-1) and the PPAR binding pro-
tein (PBP) [3, 4].
Regulation of gene transcription can occur following nu-
clear translocation of this activated complex. Transcriptional
activation or suppression can occur following recognition
of PPAR response elements (PPRE) in promoters of tar-
get genes and binding to PPRE consensus sequences com-
prising AGGTCA hexamers separated by a single nucleotide
spacer DR-1 (reviewed in [5]). Alternatively, PPAR can nega-
tively regulate gene expression by antagonizing other signal-
dependent transcription factors such as nuclear factor κB
(NFκB), CAAT/enhancer binding protein (C/EBP), signal
transducers and activators of transcription (STAT) or ac-
tivator protein 1 (AP-1). This may occur via direct bind-
ing to cause transrepression [6] or by sequestering coactiva-
tors such as the glucocorticoid receptor interacting protein-
1/transcriptional intermediary factor (GRIP-1/TIF) required
for activity of other transcription factors [7]. PPARγ lig-
ands may also mediate responses via activation of mitogen-
associated protein kinase (MAPK) and phosphoinositide-3-
kinase (PI3K) pathways [8, 9]. The diﬀerential tissue distri-
bution of PPARα,P P A R β,a n dP P A R γ as well as competition
between these isoforms and with other nuclear receptors for
the accessory proteins that regulate their activity may allow
the speciﬁc recognition of target genes and other transcrip-
tion factors to modulate cell function [3].
4. PPAR TISSUE DISTRIBUTION AND LIGANDS
PPARα,P P A R β,a n dP P A R γ are all widely expressed and
share some common ligands. However, activation of a spe-
ciﬁc PPAR can be achieved using selective ligands in tissues
where all isoforms are present or by targeting tissues where
the isoforms are diﬀerentially expressed (Tables 1, 2).
PPARαishighlyexpressedpredominantlyinliver,kidney,
skeletal muscle, and heart, and has a role in the catabolism
of fatty acids. Structurally diverse ligands for PPARα include
naturally occurring fatty acids and eicosanoids such as 8S-
hydroxyeicosatetranoic acid (8S-HETE) and leukotriene B4
(LTB4). Among the synthetic PPARα ligands described are
the ﬁbrate class of drugs used clinically for the treatment of
dyslipidaemia such as cloﬁbrate and fenoﬁbrate, and phar-
macological tools such as Wy14 643 [2].
The physiological role of PPARβ is less certain due to
its ubiquitous expression. Fatty acids also activate PPARβ,
with prostacyclin among other potential endogenous lig-
ands for PPARβ. Recently developed synthetic ligands such
as GW501516 and L165041 have been used to support a role
for PPARβ in regulation of fatty acid oxidation and cell dif-
ferentiation in skeletal muscle and adipose tissue [2, 4].
PPARγ was originally characterised as a regulator of
adipocyte diﬀerentiation, but also plays key roles in glu-
cose and lipid metabolism. Activation of PPARγ also oc-
curs in response to a wide variety of potential endogenous
ligands as well as synthetic agonists, such as the thiazo-
lidinedione (TZD) class of insulin-sensitising drugs. Nat-
urally occurring PPARγ ligands include polyunsaturated
fatty acids (PUFAs), such as linoleic acid, arachidonic acid,
and eicosapentanoic acids, and oxidised lipids such as 9-
and 13-hydroxyoctadecadienoic acid (HODE), and 12- and
15-HETE [10]. The arachidonic acid metabolite 15-deoxy-
Δ12,14-prostaglandin-J2 (15-d-PGJ2)hasbeenwidelyusedex-
perimentally to deﬁne PPARγ-dependent responses, despite
additional actions mediated through PPARα activation [11].
In this context, it is important to also note that it is still un-
certainwhetherthisprostaglandinD2 metabolitecanbegen-
erated in vivo at the micromolar concentrations suﬃcient to
mediate potential PPARγ-dependent eﬀects [12].
The TZD or glitazone class of drugs used in the treat-
ment of type 2 diabetes are believed to exert their insulin-
sensitising and hypoglycaemic eﬀects through stimulation of
PPARγ [4]. Activation of PPARγ by TZDs results in an alter-
ation in the transcription of several genes involved in glucose
and lipid utilisation such as GLUT4 glucose transporter and
fatty acid transporter protein [13], and their binding aﬃn-
ity to PPARγ closely parallels their in vivo hypoglycaemic
potency [14]. These synthetic ligands include rosiglitazone
(RGZ), ciglitazone (CGZ), pioglitazone (PGZ), and troglita-
zone (TGZ), with RGZ reported to be the most potent [15].
5. PPAR EXPRESSION AND ITS REGULATION IN
INFLAMMATORY CELLS AND IN THE LUNG
Recent evidence supports a role for PPARs in the regula-
tion of lung inﬂammation. Diﬀerential expression of PPAR
isoforms has been demonstrated in diﬀerent inﬂammatory,J. E. Ward and X. Tan 3
Table 1: Natural and synthetic ligands for PPAR isoforms.
Isoform Natural ligands Synthetic ligands Antagonists
PPARα
PGD2 Fibrates
PGI2 Wy14 643 MK866
LTB4 GW9578, GW7647 GW6471
8S-HETE NSAIDs
PPARβ PGA1 GW501516, GW0742 Sulindac
PGI2 L165041
PPARγ
PGD2,P G J 2,15-d-PGJ2 TZDs BADGE
9-HODE, 13-HODE GW262570 GW9662
12-HETE, 15-HETE NSAIDs T0070907
PPARα, γ — GW2331 —
Ragaglitazar
PPARα, β, γ Saturated FAs ——
PUFAs
BADGE: bisphenol A diglycidyl ether; FA: fatty acid; HETE: hydroxyeicosatetranoic acid; HODE: hydroxyoctadecadienoic acid; NSAID: nonsteroidal anti-
inﬂammatory drug; PUFA: polyunsaturated fatty acid; TZD: thiazolidinedione.
resident, and structural cells in the airways (see Table 2).
Both PPARα and PPARγ are expressed in macrophages and
monocytes [16–18], eosinophils [19, 20], with PPARβ also
expressed in neutrophils [21, 22]. Dendritic cells express
PPARγ but not PPARα [14, 23], but both PPARα and PPARγ
are expressed in B and T lymphocytes [24, 25]. PPARβ and
PPARγ but not PPARα are expressed in mast cells [26], while
all three isoforms have been detected in A549 and BEAS-2B
airway epithelial cell lines [27–30]. Mesenchymal expression
of PPARs has been demonstrated with PPARγ detected in
primary ﬁbroblasts [31], and with PPARα and PPARγ but
not PPARβ in airway smooth muscle [13, 32]. The variable
patterns of expression of these PPARs in these diverse cell
types suggest that receptor activation of diﬀerent isoforms
may speciﬁcally modulate both the production of media-
tors implicated in inﬂammation and the cellular responses
that contribute to tissue remodelling and the development of
AHR.
Emerging evidence suggests that PPAR receptor expres-
sion is altered in lung disease, with changes in PPARγ lev-
els being the most extensively studied. PPARγ has been lo-
calised in mucosal eosinophils and macrophages, airway ep-
ithelium and smooth muscle in human airway biopsies, with
increased expression in asthmatic patients compared with
controls [13]. In addition, in murine models of allergen-
induced inﬂammation, higher levels of PPARγ were evident
intotallungextracts[36,37]andcouldbelocalisedtoairway
epithelium and muscle cells, mast cells, and some inﬂamma-
tory cells [38].
The stimulus for the increased PPARγ levels detected
in intact airways is unclear, as is the functional role of
this increase. In vitro, PPARγ is inducible by the inﬂam-
matory cytokine interleukin-4 (IL-4) in airway epithelial
c e l l sa n dm a c r o p h a g e s[ 27, 39]. PPARγ expression in mono-
cytes is increased with macrophage diﬀerentiation and acti-
vation [16, 17] and in sensitised mast cells following anti-
gen exposure [26]. Similar changes in the cellular environ-
ment in asthmatic airways may contribute to the elevation
in PPARγ levels. The lower levels of PPARγ expression in
glucocorticoid-treated asthmatics, compared with untreated
asthmatics [13], suggest that increased PPARγ expression
may be a product of the inﬂammatory pathways sensitive
to steroid therapy. The current hypothesis is that PPARγ
expression is upregulated in response to inﬂammatory cy-
tokines to provide a negative feedback mechanism, whereby
endogenous PPARγ ligands could activate these receptors
to limit the cellular inﬂammatory response in the airways.
Increases in PPARα and PPARβ during inﬂammation have
not yet been described, although PPARβ expression in the
lung has recently been shown to be increased in the lungs of
streptozotocin-induced diabetic rats [40].
However, PPAR upregulation does not appear to be a
generalised response to inﬂammation. PPARα and PPARβ
were expressed in peripheral blood lymphocytes, monocytes,
and neutrophils healthy subjects and in patients with cystic
ﬁbrosis (CF). However, relatively lower levels and activity of
PPARα, and not PPARβ, were detected in the lymphocytes
from CF patients [22]. The authors speculate that this may
be associated with changes in levels of endogenous PPARα
ligands in CF, but that treatment with synthetic PPARα lig-
ands may increase receptor expression and activity to min-
imise the immune response [41]. Although ovalbumin sen-
sitisation has been shown to increase PPARγ expression in
the lung [36–38], levels of PPARα were decreased in in-
ﬂamed lungs of allergen-exposed mice [42]. In addition, a
recent study has shown that PPARγ mRNA and protein are
downregulated in alveolar macrophages following segmen-
tal allergen challenge in asthmatic patients, but not healthy
controls [43]. It has been suggested that this downregula-
tion could contribute to ongoing pulmonary inﬂammation,
tissue injury, and loss of function. Alternatively, it could ac-
company the reduction or resolution of inﬂammation fol-
lowing activation by PPARγ ligands since increases in PPARγ
expression induced in a murine model of asthma by aller-
gensensitisationwereinhibitedbyadministrationofthesyn-
thetic ligand, CGZ [38].4 PPAR Research
Table 2: PPAR isoforms in inﬂammatory cells and lung structural cells.
Cell type PPARα PPARβ PPARγ
Macrophage/monocyte  [16, 22]  [22, 33]  [13, 17, 18, 33]
× [33]— × [22]
Eosinophil  [19]—  [13, 19, 20]
Neutrophils  [22]  [21, 22]  [21]
—— × [22]
Lymphocytes  [22, 24, 25]  [22]  [24, 25]
—— × [22]
Dendritic cells × [14, 23]—  [14, 23]
Mast cells × [26, 34]  [26]  [26]
Epithelial cells  [28]  [28, 29]  [13, 27, 28, 30]
Lung ﬁbroblasts — —  [13, 31]
Airway smooth muscle  [32, 35] × [32, 35]  [13, 32, 35]
These studies suggest a complex interaction between the
initiation and resolution of the inﬂammatory process and
changes in PPAR receptor expression that may be regu-
lated by both inﬂammatory mediators and the levels of en-
dogenous PPAR ligands. It is important therefore to deﬁne
receptor-mediated responses at both the cellular level and in
integrated animal models of disease to elucidate the role for
PPARs in lung inﬂammation.
Against this translational background, the development
ofselectiveligandsforPPARisoformshasbeencritical.How-
ever, there are marked diﬀerences between reported binding
aﬃnities and receptor activation potencies for PPAR ligands
versus the concentrations required to elicit cellular eﬀects.
Multiple approaches are therefore required to support claims
for PPAR-dependency of these actions. These include con-
ﬁrming receptor expression in cells of interest and the use of
pharmacological antagonists. Several irreversible antagonists
for PPARγ have been described including bisphenol A digly-
cidyl ether (BADGE) [44], and GW9662 [45], although the
utility of the former may be compromised by its partial ago-
nist activity [46]. Antagonists for other PPAR isoforms have
been described (see Table 1), but have not been utilised in
studies outlined in this review.
More recently, molecular techniques have been used to
characterise potential PPAR-mediated responses. Adenoviral
constructs expressing a dominant negative PPARγ gene that
binds to the ligand and the PPRE on DNA but does not ini-
tiate transcription have been used in lung ﬁbroblasts [31],
while the eﬀects of overexpression of functional PPARγ have
been assessed in murine models of asthma [36, 37, 47]. In
vivo, transgenic approaches have also characterised the regu-
latory role of PPARα in inﬂammation using PPARα-deﬁcient
mice [19, 48]. A similar approach for PPARγ is not pos-
sible, since complete elimination of this isoform results in
embryonic lethality. However, heterozygous knockout mice
(PPARγ+/−) have been generated [49] and used to impli-
cate PPARγ in mast cell proliferation [50]. More recently,
a developmental study using mice with speciﬁc ablation of
PPARγ in the airway epithelium showed that these condi-
tionally PPAR−/−-targeted mice had reduced collagen extra-
cellular matrix (ECM) gene expression in the lung [51]. This
suggeststhatPPARγ hasaroleintheepithelial-mesenchymal
interactions necessary for the establishment of normal lung
structure[51].Theimplicationsofthisﬁndingoninﬂamma-
tion in lung disease have yet to be explored.
6. PPAR FUNCTION IN INFLAMMATORY
CELLS AND IN THE LUNG
There is now extensive evidence that PPAR ligands reg-
ulate inﬂammatory and immune processes mediated by
c e l l si nw h i c ho n eo rm o r eP P A Ri s o f o r m si se x p r e s s e d .
Many of these actions are in common with corticosteroids,
which have been shown to have inhibitory eﬀects on T cell,
eosinophil, neutrophil, mast cell/basophil, and macrophage
function [52]. PPAR ligands have also been shown to af-
fect cellular responses of resident and structural cells im-
plicated in inﬂammation and tissue remodelling in chronic
lung diseases. Most of these studies have focussed on PPARγ,
and some direct comparisons have been made with corticos-
teroids [32, 53]. In many cases it remains to be determined
whether the eﬀects of PPAR ligands are receptor-mediated,
to clarify diﬀerences in the activities and mechanisms of ac-
tion of putative endogenous ligands and synthetic agonists,
and to determine their potential therapeutic advantages over
corticosteroids.
A characteristic feature of airway inﬂammation in
asthma is the predominance of Th2 lymphocytes and their
products, which mediate inﬂammatory cell recruitment of
mast cells, eosinophils, and lymphocytes and subsequent re-
lease of mediators from these cells. Both 15-d-PGJ2 and CGZ
are reported to inhibit T cell proliferation [24, 54]. 15-d-
PGJ2 but not CGZ or PPARα agonists induced T cell apopto-
sis [55]. 15-d-PGJ2 also decreased production of both Th1
and Th2 type cytokines from T cells [56]. In addition, T
cellsobtainedfromsensitised micetreatedwithCGZshowed
decreased IFNγ, IL-4, and IL-2 release when exposed to al-
lergen [56]. However, 15-d-PGJ2 also caused a potentially
proinﬂammatory induction of IL-8 gene expression in hu-
man T cells and macrophages via a MAPK and/or NFκB-
dependent signalling pathway [8, 57].J. E. Ward and X. Tan 5
In activated monocytes, the PPARγ ligands 15-d-PGJ2
and TGZ inhibited production of proinﬂammatory cy-
tokinestumournecrosisfactorα(TNFα),interleukin-1β(IL-
1β) and IL-6 [58]. In contrast, natural and synthetic agonists
for PPARα were ineﬀective in these cells [58]. 15-d-PGJ2 and
RGZ also reduced TNFα release and the expression of in-
ducible nitric oxide synthase (iNOS) and matrix metallopro-
teinase(MMP)-9inactivatedmacrophages,inpartbyantag-
onising the activities of AP-1, STAT, and NFκB[ 17, 33]. Both
PPARα and PPARγ agonists induced macrophage apoptosis,
in cells stimulated with TNFα and IFNγ [16].
6.1. Eosinophils
Eosinophils are elevated in the airways of asthmatics and
canreleaseinﬂammatoryandcytotoxicmediators,cytokines,
and growth factors that contribute to tissue remodelling and
AHR. IL-5 and eotaxin-induced chemotaxis were reduced
by PPARα-a n dP P A R γ-selective ligands Wy14 643 and RGZ
at micromolar concentrations, with the eﬀect of RGZ pre-
vented by the PPARγ antagonist, GW9662 [19]. In contrast
to these ﬁndings, it has recently been shown that both 15-
d-PGJ2 and TGZ prime eotaxin-induced chemotaxis in the
picomolar to low nanomolar concentration range, and that
this eﬀect is also prevented by GW9662 [59]. The possibility
that endogenous ligands may have proinﬂammatory eﬀects
via PPARγ at physiological concentrations, but that exoge-
nous ligands may be negative immunomodulators at higher
concentrations,willrequirefurtherinvestigation.Thisexpla-
nation may also resolve discrepancies in other in vitro stud-
ies examining regulation of cytokine release and expression
that ascribe both pro- and anti-inﬂammatory properties to
PPARγ ligands.
6.2. Mastcells
Mast cell inﬁltration of airway smooth muscle (ASM) in the
airway wall is associated with impaired function in asthma
[60]. In response to antigen stimulation, mast cells release
storedmediatorssuchashistamine,andproducearachidonic
acid derivatives such as prostaglandins and leukotrienes, and
cytokines such as TNFα, IL-4, and granulocyte macrophage-
colony stimulating factor(GM-CSF). Several roles for PPARs
in regulation of mast cell function have been proposed. The
PPARβ ligand carbaprostacyclin and PPARγ ligands 15-d-
PGJ2 and TGZ suppressed histamine release and TNFα and
GM-CSF production by human basophilic KU812 cells and
mastcells[26,61].Inaddition,theincreaseincellsurfaceex-
pression of the high aﬃnity IgEreceptorFcεRIinresponseto
antigen was reduced by selective PPARβ and PPARγ ligands,
namely PGA1 and 15-d-PGJ2 [61]. PPARα ligands had no ef-
fect on cytokine release or FcεRI expression in these human
cells [26, 61]. Although fenoﬁbrate, Wy14 643, and CGZ in-
hibited antigen-induced leukotriene production from rat ba-
sophilic leukemia (RBL)-2H3 cells, these eﬀects are likely to
be PPAR-independent since PPARα mRNA was below detec-
tion [34] and the inhibition by CGZ was not prevented by
aP P A R γ antagonist or associated with nuclear translocation
of the receptor [62]. However, proliferation of bone-marrow
derived murine mast cells was increased by RGZ in an ap-
parently PPARγ-dependent manner, since it was prevented
by the PPARγ antagonist GW9662 and the eﬀect of RGZ was
reduced in cells from PPARγ+/− mice [50].
Further studies are required to explore the mechanisms
of action of these selective PPARβ and PPARγ ligands, and to
clarify the role of both receptors in the modulation of mast
cell function. Previous in vivo studies suggest that corticos-
teroids have a minimal eﬀect on mast cell degranulation and
the appearance of mast cell mediators after segmental anti-
gen challenge in subjects with asthma [63].
6.3. Epithelialcells
Epithelial remodelling has been documented early in the de-
velopment of asthma. Airway epithelial cells can contribute
to persistent inﬂammation through synthesis and secretion
of enzymes and mediators that regulate matrix turnover and
inﬂammatory cell inﬂux. Potential anti-inﬂammatory ac-
tions for PPARγ ligands have been described in various ep-
ithelial cell lines. RGZ and PGZ decreased TNFα-a n dp h o r -
bol myristate acetate (PMA)-induced MMP-9 activity levels
in NL20 and BEAS cells, associated with inhibition of NFκB
activation [30]. In A549 cells, TZDs reduced expression of
iNOS [27] and decreased secretion of Regulated upon Ac-
tivation, Normal T-cell Expressed, and Secreted (RANTES)
and IL-8 [27, 64]. In contrast to these studies, both RGZ
and TGZ potentiated TNFα-induced production of proin-
ﬂammatory cytokines GM-CSF, IL-6 and IL-8 from A549
cells, independently of PPARγ,N F κBo rM A P Ka c t i v a t i o n
[65].
There is also a complex relationship between PPARγ
and cyclo-oxygenase-2 (COX-2) expression in airway epithe-
lial cells. Both RGZ and CGZ inhibited increases in PMA-
induced COX-2 expression by inhibiting AP-1 signalling
[66]. However, TGZ increased basal and TNFα-induced
COX-2 expression independently of PPARγ and NFκB, but
dependent on PI3K and ERK MAPK pathways in A549 cells
[9]. In this study, neither 15-d-PGJ2 nor RGZ (PPARγ lig-
ands), GW262570 (PPARγ/αagonist),nor L-165041 (PPARβ
agonist) regulated COX-2 expression. Further investigation
of these discrepancies will be required to deﬁne the eﬀects of
PPARγ ligands on airway epithelial cells and the mechanisms
by which these pro- and/or anti-inﬂammatory responses oc-
cur.
6.4. Mesenchymalcells
Fibroblasts play an important role in regulation of ECM de-
position that contributes to subepithelial ﬁbrosis layer of the
airway, and the development of ﬁxed airway obstruction in
asthma [67]. Thickening of the ASM layer is another char-
acteristic feature of airway remodelling in asthma. This has
been associated with ASM hypertrophy and/or hyperplasia
[68, 69] and increased ECM deposition within the ASM
bundle [70]. These cells can respond to both mitogens and
inﬂammatory mediators and contribute to further changes
in the airway through the production of ECM proteins, cy-
tokines, and chemokines. The PPARγ ligands RGZ, CGZ,6 PPAR Research
and 15dPGJ2 inhibited the diﬀerentiation of human lung
ﬁbroblastsintomyoﬁbroblastsandreducecollagenIproduc-
tion following TGFβ stimulation, although the PPARα lig-
and Wy14 643 was ineﬀective [31]. These potential antiﬁ-
brotic eﬀe c t sm a yb eo n l yp a r t l ym e d i a t e db yP P A R γ, since
they were suppressed by expression of a dominant negative
PPARγ construct, but not by GW9662 [31]. It has been re-
ported that corticosteroids did not prevent TGFβ-induced
collagen I production by ASM cells from individuals with or
without asthma [71], and this suggests that PPARγ agonists
may have a therapeutic advantage over corticosteroids in the
regulation of lung ﬁbrosis.
In ASM, the PPARγ agonists 15-d-PGJ2 and CGZ sup-
pressed both GM-CSF and G-CSF release [32, 53]. Inter-
estingly, the proﬁle of inﬂammatory mediator inhibition
diﬀered between CGZ and corticosteroids, as dexametha-
sone inhibited GM-CSF but not G-CSF levels [32, 53]. In
a separate study, 15-d-PGJ2 and TGZ were shown to in-
hibit TNFα-induced production of eotaxin and monocyte
chemotactic protein-1 (MCP-1) but not IL-8 secretion from
ASM [53]. The inhibitory eﬀects of 15-d-PGJ2 were addi-
tive with ﬂuticasone, oﬀering the intriguing possibility that
PPARγ agonists in combination with corticosteroids may
provide additional therapeutic beneﬁt in asthma [53]. Al-
though PPARγ heterodimerisation with the retinoid X re-
ceptor is well characterized, this study also described addi-
tional complexity in the mechanisms of action of PPARγ ag-
onists, with direct physical interactions between PPARγ and
GR [53]. In addition, PPARγ agonists were shown to me-
diate anti-inﬂammatory eﬀects directly via GR activation,
with RGZ and CGZ stimulating GR nuclear translocation in
aP P A R γ deﬁcient cell line [72]. Assessment of these poten-
tial interactions between PPARγ and GR by receptor translo-
cation studies may provide additional insights into mecha-
nisms underlying the relative activities of nuclear receptor
agonists in ASM.
PPARγ agonists CGZ and 15-d-PGJ2 increased COX-2
expression in ASM, by binding to the PPRE in the COX-2
promoter [35]. Despite the proposed proinﬂammatory role
for this enzyme, the increased PGE2 levels following induc-
tionofCOX-2mayactinanautocrinemannertoreducesub-
sequent production of GM-CSF, and to inhibit proliferation
of ASM [73, 74].
PPARγ ligands may also exert direct antimitogenic ac-
tions that could inhibit airway remodelling. Both 15-d-
PGJ2 and TZDs inhibited proliferation of human cultured
ASM cells [32, 75]. The eﬀects of 15-d-PGJ2 and RGZ were
mitogen-independent, as each ligand decreased FGF2- and
thrombin-mediated proliferation with similar potency [75].
However, only the eﬀects of RGZ were reversed by the selec-
tive PPARγ antagonist GW9662 [75]. RGZ caused inhibition
of cell-cycle progression in late G1 phase, without decreasing
mitogen-stimulated cyclin D1 protein levels, a mechanism
that diﬀers from dexamethasone [76]. Of additional interest,
thedegreeofinhibition ofserum-inducedASMproliferation
was greater for CGZ than dexamethasone [32]. It is critical
to extend these comparisons to cells derived from asthmatics
where the ability of corticosteroids to inhibit proliferation is
reduced [77] to determine whether PPARγ provides an addi-
tional or alternative therapeutic target to glucocorticoid re-
ceptors to regulate remodelling in asthma.
PPARα was also expressed in ASM, but surprisingly,
Wy14 643 did not regulate inﬂammatory cytokine produc-
tion [32, 53], COX-2 expression [35], or proliferation [32,
77] of these cells.
7. PPAR REGULATION OF ALLERGEN-INDUCED
INFLAMMATION IN VIVO
On the basis of these in vitro ﬁndings in inﬂammatory and
structural cells, the role of PPARs has now been explored in
murine models of allergen-induced bronchial inﬂammation.
Although these models do not recapitulate all the patho-
physiological changes seen in asthma, sensitisation and re-
peated aerosol challenges with ovalbumin (OVA) induce air-
way eosinophilia, changes in airway structure and increases
in airways reactivity. Numerous studies have now utilised
syntheticPPARligands,adenoviralconstructscarryingPPAR
cDNA (AdPPAR) and transgenics to support immunomod-
ulatory roles for PPARs in the regulation of inﬂammation,
airway wall remodelling, and hyperresponsiveness. Although
the majority of studies have focussed on PPARγ, some com-
parisons have been made with the other PPAR isoforms.
7.1. PPARα
In PPARα-deﬁcient Balb/c mice sensitized and challenged
with OVA, there were greater increases in lung inﬂamma-
tion,airwayeosinophilia,andantigen-speciﬁcserumIgElev-
els than in wild-type OVA-treated mice [19]. This was asso-
ciated with relatively higher IL-6, IL-13, and eotaxin levels
in the lung, although IL-4, IL-5, and soluble vascular and
celladhesionmolecule-1(sVCAM-1)werenotdiﬀerent[19].
Critically, the PPARα-deﬁcient Balb/c mice also displayed a
greater response to MCh after OVA-sensitization and aerosol
challenge than wild-type mice, providing a functional cor-
relate to the cellular and humoral changes [19]. It was sug-
gested that this PPARα deletion worsened eosinophilia and
asthma-like symptoms by preventing the anti-inﬂammatory
actions mediated by the endogenous PPARα ligand, LTB4,
known to be produced abundantly by mast cells and other
cell types in asthma. A separate study utilising a selective
PPARα ligand provides support for this explanation, since
GW9578 inhibited allergen-induced inﬂux of eosinophils
andlymphocytes[28].Inthesamestudy,theselectivePPARβ
agonist GW501516 had no eﬀect on inﬂammatory cell inﬂux
[28].
There are conﬂicting reports on the role of PPARα in
regulating airway inﬂammation induced by lipopolysaccha-
ride (LPS), which is characterised by inﬁltration of neu-
trophils and macrophages, increased chemoattractant lev-
els, and elevated MMP activity in BALF. Although GW8578
had no eﬀect on neutrophil inﬂux or increased levels of ker-
atinocyte derived-chemokine (KC) or TNFα following LPS
treatment [28], fenoﬁbrate reduced the increase in BALF
n e u t r o p h i l sa n dm a c r o p h a g e sa sw e l la sl e v e l so fT N F α,
KC, macrophage inﬂammatory protein-2 (MIP-2), mono-
cyte chemoattractant protein-1 (MCP-1) and both MMP-2J. E. Ward and X. Tan 7
and MMP-9 activities [78]. Further studies are required to
conﬁrm if PPARα activation may also have a beneﬁcial eﬀect
in acute or chronic inﬂammatory airway disorders involving
neutrophils and macrophages.
7.2. PPARγ
7.2.1. Inﬂammation
In Balb/c mice sensitized and challenged with OVA, PPARγ
ligands reduced levels of proinﬂammatory mediators in the
bronchoalveolar lavage (BAL) ﬂuid and lung [19, 28, 36, 37,
56] (see Figure 1). Signiﬁcantly, cytokines associated with
Th2-driven humoral responses were decreased by treatment
with synthetic PPARγ ligands. Increased levels of IL-4, IL-5,
IL-13, and eosinophil cationic protein were reduced by the
administration of RGZ or PGZ [36, 37]. In addition, in vitro
studies of T cell obtained from sensitised mice treated with
CGZ showed decreased IL-4 release when exposed to aller-
gen [56].
Although the antigen sensitisation protocol diﬀered, a
common ﬁnding in these studies in Balb/c mice has been
that PPARγ ligands CGZ, RGZ and PGZ, and administra-
tion of AdPPARγ reduced the OVA-induced inﬂux of inﬂam-
matory cells, speciﬁcally eosinophils [19, 28, 36–38, 47] (see
Figure 1).However,inC57BL/6mice,RGZtreatmenthadno
eﬀect on levels of inﬂammatory cells in the bronchoalveo-
lar lavage ﬂuid despite inhibiting airways hyperresponsive-
ness [79]. Whether this is a strain diﬀerence in sensitivity to
regulation of this measure of airway inﬂammation, or relates
to the ligand and/or route of administration used is yet to be
clariﬁed.
7.2.2. Airwayremodelling
Airway wall remodelling is characterised by goblet cell meta-
plasia, collagen deposition and subepithelial ﬁbrosis, and
smooth muscle hypertrophy and/or hyperplasia. The role of
PPARγ in regulating these changes has been explored. Treat-
ment of Balb/c mice with nebulised CGZ was associated
with a reduction in mucous production [38] (see Figure 1).
Since orally administered CGZ had no eﬀect [56]a n do r a l
RGZ treatment had no impact on goblet cell hyperplasia in
C57BL/6 mice [79], the route of administration may be crit-
ical to regulate this parameter.
There is now evidence that activation of PPARγ may reg-
u l a t eE C Md e p o s i t i o nt h a to c c u r si na i r w a yw a l lr e m o d -
elling. CGZ decreased basement membrane thickness and
airways collagen deposition in response to antigen sensiti-
zation and challenge, associated with a reduction in TGF-β
synthesis [38]. Inhibition of TGF-β signalling has also previ-
ously been shown to be inhibited by CGZ in cultured lung
ﬁbroblasts [31]. In support of a generalised antiﬁbrotic ac-
tivity for PPAR ligands, both RGZ and Wy14 643 have been
shown to reduce bleomycin-induced pulmonary ﬁbrosis in
mice [18, 48, 80].
TheantiﬁbroticeﬀectofCGZseeninvivomayalsobere-
latedtoregulationoftheactivityofMMPsortheirinhibitors.
Although an increase in MMP-2 proteolytic activity in the
BALF with OVA treatment was not aﬀected by RGZ [79], it
has previously been reported that RGZ inhibits MMP-9 ex-
pression in bronchial epithelial cell lines [30].
Further studies are required to assess whether the in-
hibitory eﬀects of TZDs on ASM proliferation translate to
the in vivo setting, where antigen sensitization and challenge
leads to inﬂammation, airway ﬁbrosis, and thickening of the
ASM layer. This is critical since the ability of corticosteroids
toreduceairwaystructuralchangesinmurinemodelsisvari-
able[81,82],andairwayremodellingpersistsdespiteoptimal
clinical use of corticosteroids in asthmatic patients [83].
7.2.3. Airwayshyperresponsiveness
The impact of regulation of these markers of inﬂamma-
tion and tissue remodelling by PPARγ ligands on AHR has
alsobeenexplored.Usingunrestrainedplethysmography,the
methacholine (MCh)-induced increase in enhanced pause
(Penh)hasbeenusedasameasureofAHRfollowingallergen
sensitisation and challenge. In Balb/c mice, nebulized CGZ,
oral RGZ, or oral PGZ completely prevented the increased
response to MCh [19, 36–38, 47]. The eﬀects of the synthetic
PPARγ ligands were mimicked by AdPPARγ [36, 37, 47]a n d
abrogated by GW9662 [19, 36–38, 47].
Using invasive measurements of respiratory resistance
and compliance, RGZ reduced the increase in airways re-
sistance after OVA challenge in C57BL/6 mice, without af-
fecting the decrease in lung compliance, reﬂecting an eﬀect
on the airways rather than the parenchyma of the lung [79].
This ﬁnding provides further support for the proposed role
of PPARγ in the regulation of AHR, and is important in
light of recent criticism of the use of Penh measurements to
draw conclusions about the eﬀects of potential therapeutic
agents on AHR [84]. However, since this inhibition by RGZ
occurred in the absence of a signiﬁcant eﬀect on the OVA-
inducedincreaseinBALinﬂammatorycells,MMP-2activity,
and goblet cell number, it is possible that RGZ may modu-
late AHR by a mechanism that is independent of inhibition
of inﬂammatory cell recruitment to the airway [79]. Disso-
ciation between inhibition of eosinophilia and reduction in
AHR have previously been reported, although the dose of
dexamethasonerequiredtoinhibitAHRwashigherthanthat
needed to inhibit eosinophilia in a murine model of allergic
airway inﬂammation [85].
7.2.4. Potentialmechanismsfordecreasedinﬂammation
andAHRbyPPARγ ligands
MCh reactivity was unchanged in saline-challenged mice af-
t e ro r a lt r e a t m e n tw i t hR G Zf o r7d a y s[ 79], suggesting that
exposure of ASM to RGZ does not directly inhibit con-
tractile responsiveness. In addition, RGZ did not modulate
basal airway tone, or the contraction in response to MCh or
histamineinisolatedguineapigtrachealrings[79].However,
CGZ and RGZ have been shown to produce concentration-
dependent relaxation smooth muscle of isolated mouse tra-
chea [86]. This eﬀect was not prevented by GW9662, but was
inhibited by indomethacin, and suggested that TZDs could
act independently of PPARγ to inhibit PGE2 metabolism by8 PPAR Research
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Figure 1: Proposed eﬀects of PPARγ ligands on inﬂammatory and remodelling changes in the asthmatic airway that contribute to airways
hyperresponsiveness.
15-hydroxyprostaglandin dehydrogenase leading to a dilator
response [86, 87].
A series of studies have shown that inhibitory eﬀects
of TZDs and AdPPARγ on both eosinophilia and AHR
were prevented by GW9662 and implicate increases in phos-
phatase and tensin homologue deleted on chromosome
ten (PTEN) and IL-10 in the protective roles of PPARγ-
activation [36, 37, 47]. This is in agreement with a sepa-
rate study, in which RGZ inhibited the migration of antigen-
loaded dendritic cells in the mediastinal lymph nodes and
increased IL-10 production [88].
8. SUMMARY
On the basis of these in vitro and in vivo ﬁndings, substantial
evidencehasemergedtoprovideproof-of-conceptforthefu-
ture clinical application of PPARγ ligands to treat airway in-
ﬂammation.Giventheirlongrecordofuseintype2diabetes,
TZDs appear to be ideally placed for use in the treatment
of chronic lung disease. Like corticosteroids, they appear to
have broad anti-inﬂammatory eﬀects and possess potential
anti-remodelling eﬃcacy on multiple cell types in the lung
and in animal models of asthma. However, PPARγ agonists
includingRGZmayoﬀeradditionaltherapeuticaladvantages
to current treatment, if they can be proven to exert control
over proinﬂammatory and proasthmatic pathways that are
not susceptible to inhibition by corticosteroids in the clinical
setting. Further comparative studies are required to explore
these novel complementary or additional actions of PPARγ
agonists to those already identiﬁed.
The eﬃcacy of TZDs in asthma has not yet been eval-
uated in human clinical studies, although there has been a
case report describing the reduction in asthma symptoms in
patients treated with PGZ for diabetes [89]. A limited trial
examining the eﬀect of RGZ on lung function in comparison
with low dose inhaled corticosteroids in steroid na¨ ıve smok-
ers with asthma is currently underway in the United King-
dom to determine whether targeting PPARγ may oﬀer ther-
apeutic beneﬁt in the future treatment of asthma and other
inﬂammatory lung diseases.
ABBREVIATIONS
AHR: Airways hyperresponsiveness
AP-1: Activator protein-1
ASM: Airway smooth muscle
BADGE: Bisphenol A diglycidyl ether
BALF: Bronchoalveolar lavage ﬂuid
C/EBP: CAAT/enhancer binding protein
CF: Cystic ﬁbrosis
CGZ: Ciglitazone
COX-2: Cyclo-oxygenase-2
15-d-PGJ2 : 15-deoxy-Δ12,14-prostaglandin J2
ECM: Extracellular matrix
ERK: Extracellular regulated kinase
FA: Fatty acid
FGF-2: Fibroblast growth factor-2
G-CSF: Granulocyte colony stimulating
factor
GM-CSF: Granulocyte-macrophage colony
stimulating factor
GR: Glucocorticoid receptor
GRIP-1: Glucocorticoid receptor interacting
protein-1
HETE: Hydroxyeicosatetranoic acid
HODE: Hydroxyoctadecadienoic acid
IFNγ :I n t e r f e r o n γ
iNOS: Inducible nitric oxide synthase
KC: Keratinocyte-derived chemokine
LPS: LipopolysaccharideJ. E. Ward and X. Tan 9
LTB4: Leukotriene B4
MAPK: Mitogen-associated protein kinase
MCh: Methacholine
MCP-1: Monocyte chemotactic protein-1
MIP-2: Macrophage inﬂammatory protein-2
MMP: Matrix metalloprotease
NFκB: Nuclear factor κB
NSAID: Nonsteroidal anti-inﬂammatory drug
OVA: Ovalbumin
PGZ: Pioglitazone
PI3K: Phosphoinositide-3-kinase
PMA: Phorbol myristate acetate
PPAR: Peroxisome proliferator activated
receptor
PPRE: Peroxisome proliferator activated
receptor response element
PUFA: Polyunsaturated fatty acid
PTEN: Phosphatase and tensin homologue
deleted on chromosome ten
RANTES: Regulated upon activation normal T
cell expressed and secreted
RGZ: Rosiglitazone
RXR: Retinoid X receptor
STAT: Signal transducers and activators of
transcription
sVCAM-1: Soluble vascular and cell adhesion
molecule-1
TGFβ : Transforming growth factorβ
TGZ: Troglitazone
TIF: Transcriptional intermediary factor
TNFα : Tumour necrosis factorα
TZD: Thiazolidinedione
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